Pacific Biosciences of California, Inc. (PACB) Q2 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, and welcome to the PACBio second quarter 2023 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one. To withdraw your question, you may press star, then two. Please note, this conference is being recorded. I would now like to turn the call over to Todd Friedman, Head of Investor Relations. Please go ahead. Thanks, MJ. Good afternoon, and welcome to PACBio's second quarter 2023 earnings conference call. Earlier today, we issued a press release outlining the financial results we will be discussing on today's call. a copy of which is available in the investor section of our website at www.tacb.com or is furnished on Form 8K available on the Securities and Exchange Commission website at www.sdc.gov. With me today are Christian Henry, President and Chief Executive Officer, and Susan Kim, Chief Financial Officer. Before we begin, I would like to remind you that on today's call, we will be making forward-looking statements, including statements regarding predictions, progress, estimates, plans, intentions, guidance, and others, including expectations regarding our financial guidance and operating plans, our REVIO and ONZO systems and their commercialization plans, the future availability, uses, accuracy, coverage, advantages, quality or performance of, or benefits or expected benefits, of using PacBio products or technologies, including our Revio and Anzo systems, expectations with respect to our acquisition of Aptom Biosciences and its products and technologies, and expectations with respect to customer demand of our pro...